Immunocore to Present at Upcoming Investor Conferences
Immunocore to Present at Upcoming Investor Conferences
The presentations will be webcast live and can be accessed by visiting 'Events & Presentations', under 'Events', via the 'Investors' section of Immunocore's website at . Following the event, a replay of the presentations will be made available for a limited time.(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.
(英国牛津郡，宾夕法尼亚康肖霍肯，美国盖瑟斯伯格，马里兰州，2024年11月8日) 爱文思控股有限公司（纳斯达克股票代码: IMCR）（"爱文思控股"或"公司"），一家商业阶段的生物技术公司，致力于开拓和提供革命性的免疫调节药物，从根本上改善癌症、传染病和自身免疫疾病患者的预后，今日宣布管理层将参加以下投资者会议:
Guggenheim Securities Healthcare Innovation Conference
Fireside Chat: Tuesday, November 12, 2024, at 1:00 p.m. EST
古根海姆证券医疗健康创新会议
炉边聊天: 2024年11月12日，美国东部时间下午1点
Jefferies London Healthcare Conference
Fireside Chat: Wednesday, November 21, 2024, at 9:00 a.m. GMT
Jefferies伦敦医疗健康会议
炉边聊天: 2024年11月21日，格林尼治标准时间上午9点
The presentations will be webcast live and can be accessed by visiting 'Events & Presentations', under 'Events', via the 'Investors' section of Immunocore's website at . Following the event, a replay of the presentations will be made available for a limited time.
演示将通过访问Immunocore网站的“投资者”部分下的“活动”中的“事件与演示”进行网络直播。活动结束后，演示的回放将在有限时间内提供。
About Immunocore
关于Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company's most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Immunocore是一家商业化阶段的生物技术公司，致力于开发一种新型的TCR双特异性免疫疗法，称为ImmTAX -免疫活化单克隆TCR对抗X疾病 - 旨在治疗广泛的疾病，包括癌症，自身免疫病和传染病。借助其专有的、灵活的、现成的ImmTAX平台，Immunocore正在多个治疗领域开发深层次的产品线，包括肿瘤学和传染病的五个临床阶段项目，自身免疫病的先进临床前项目和多个早期临床前项目。该公司最先进的肿瘤学TCR疗法KIMMTRAk已经在美国，欧盟，加拿大，澳大利亚和英国获得批准，用于治疗HLA-A * 02:01阳性的成年患者无法切除或转移的葡萄膜黑色素瘤。
Contact Information
联系信息
Immunocore
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Sébastien Desprez，通信部总监
T：+44 (0) 7458030732
E: sebastien.desprez@immunocore.com
在Twitter上关注：@Immunocore
Investor Relations
投资者关系
Clayton Robertson, Head of Investor Relations
T: +1 (215) 384-4781
E: ir@immunocore.com
投资者关系主管Clayton Robertson
电话：+1（215）384-4781
E: ir@immunocore.com
